<DOC>
	<DOCNO>NCT02249741</DOCNO>
	<brief_summary>Background Objectives : Patients liver cirrhosis prone develop reduce bone mineral density i.e . hepatic osteodystrophy ( HOD ) . It include osteopenia osteoporosis may lead increased fracture risk . There scanty data prevalence HOD Indian population treatment outcome . The investigator aim determine prevalence HOD , factor associate impact bisphosphonates bone mineral density patient liver cirrhosis . Patients Methods : Consecutive patient liver cirrhosis admit Sir Ganga Ram Hospital , New Delhi August 2012 July 2013 enrol . Patients chronic kidney disease , hyperparathyroidism steroid exclude . Bone mineral density ( BMD ) measure dual-energy X-ray absorptiometry ( DEXA ) lumbar spine femoral neck . Osteopenia osteoporosis define accord WHO criterion . All patient also underwent 25-hydroxy-vitamin-D , sex hormone ( testosterone male LH Estradiol female ) parathyroid hormone ( PTH ) along routine investigation . Transient elastography also do patient . Ibandronic acid 150 mg per day orally six month give patient osteoporosis DEXA scan repeat .</brief_summary>
	<brief_title>Prospective Study Profile Hepatic Osteodystrophy Patients With Non-Choleastatic Liver Cirrhosis Impact Bisphosphonate Supplementation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Liver Cirrhosis 2 . Age 1870 year 3 . Informed write consent 1 . Chronic renal failure 2 . Prolonged steroid use 3 month 3 . Patients immunosuppressive therapy 4 . Primary hyperparathyroidism 5 . Post menopausal woman 6 . Pregnancy 7 . Cushing 's syndrome 8 . Malignancy 9 . HIV Coinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>